(Q38105939)

28 August 2017

title

Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review (English)

1 reference

28 August 2017

main subject

Guillain–Barré syndrome

0 references

TNF inhibitor

0 references

TNF

0 references

author

Bonifacio Alvarez-Lario

object named as

Bonifacio Alvarez-Lario

1

0 references

author name string

Rosa Prieto-Tejedo

2

1 reference

28 August 2017

María Colazo-Burlato

3

1 reference

28 August 2017

Jesús Macarrón-Vicente

4

1 reference

28 August 2017

publication date

11 May 2013

1 reference

28 August 2017

published in

Clinical Rheumatology

1 reference

28 August 2017

volume

32

1 reference

28 August 2017

issue

9

1 reference

28 August 2017

page(s)

1407-1412

1 reference

The value of early intervention in RA--a window of opportunity

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between 2001 and 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Tumor necrosis factor-alpha antagonists and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Guillain-Barré and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Guillain-Barre in a patient with ankylosing spondylitis secondary to ulcerative colitis on infliximab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Guillain-Barré syndrome: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

21 January 2018

Guillain–Barré Syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

21 January 2018

Guillain-Barré syndrome

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

TH1 and TH2 response to Campylobacter jejuni antigen in Guillain-Barre syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Long term disability and social status change after Guillain-Barré syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Campylobacter jejuni infection and Guillain-Barré syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Harmful effects of anti-GalNAc-GD1a antibodies and TNF-alpha on rat dorsal root ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Inflammatory neurological disease in patients treated with tumor necrosis factor alpha inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Pathogenesis of Guillain-Barre syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Neurological adverse events associated with anti-tumor necrosis factor α treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Tumor necrosis factor alpha (TNF-α), anti-TNF-α and demyelination revisited: an ongoing story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

A method for estimating the probability of adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Approaches for identifying and defining environmentally associated rheumatic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

New-onset multiple sclerosis associated with adalimumab treatment in rheumatoid arthritis: a case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Rituximab-responsive Guillain-Barré syndrome following allogeneic hematopoietic SCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10067-013-2272-9

Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group

21 January 2018

1 reference

12 December 2020

Long-term impact on work and private life after Guillain-Barré syndrome

1 reference

12 December 2020

[Guillain-Barré syndrome. Its association with alpha tumor necrosis factor]

1 reference

12 December 2020

The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group

1 reference

12 December 2020

Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al

1 reference

12 December 2020

Guillain-Barré syndrome in a patient receiving anti-tumour necrosis factor alpha for rheumatoid arthritis: a case report and discussion of literature

1 reference

12 December 2020

Correlation of matrix metalloproteinases-2 and -9 with proinflammatory cytokines in Guillain-Barré syndrome

1 reference

12 December 2020

Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma

1 reference

12 December 2020

Demyelinating events in rheumatoid arthritis after drug exposures

1 reference

12 December 2020

Pattern of demyelination occurring during anti-TNF-α therapy: a French national survey

1 reference

12 December 2020

Guillain-Barré syndrome following adalimumab treatment

1 reference

12 December 2020

Multiple sclerosis and chronic inflammatory diseases. A case-control study

1 reference

12 December 2020

[Meningeal and Guillain-Barrè syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy]

1 reference

12 December 2020

10.1007/S10067-013-2272-9

Identifiers

DOI

1 reference

28 August 2017

1 reference